Skip to main content

#160574

Anti-neurofilament M IgG1 (neurofilament medium polypeptide) [NF-08]

Cat. #160574

Anti-neurofilament M IgG1 (neurofilament medium polypeptide) [NF-08]

Cat. #: 160574

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Neurofilament M

Class: Monoclonal

Application: WB ; IHC

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Pavel Draber

Institute: Institute of Molecular Genetics CAS

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-neurofilament M IgG1 (neurofilament medium polypeptide) [NF-08]
  • Alternate name: NF-M; NEFM; Neurofilament medium polypeptide
  • Research fields: Cell biology
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Purpose: Marker
  • Conjugation: Unconjugated
  • Host: Mouse
  • Application: WB ; IHC
  • Description: Monoclonal antibody against neurofilament M
  • Immunogen: Pig brain protein
  • Immunogen uniprot id: P08552 (NFM_PIG)
  • Isotype: IgG1

Target Details

  • Target: Neurofilament M
  • Tissue cell line specificity: Mouse
  • Target background: Monoclonal antibody against neurofilament M

Applications

  • Application: WB ; IHC

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • Porchet et al. 2003. Neuroreport. 14(7):929-33. PMID: 12802177.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.